Walker Neal 4

What Happened

• Neal Walker, CEO and Director of Aclaris Therapeutics (ACRS), had 63,475 restricted stock units (RSUs) settle on February 3, 2026.
• Of those, 18,611 shares were withheld to cover tax withholding at $3.47 per share, totaling $64,580, leaving a net of 44,864 shares added to his holdings.
• This was an award settlement (vesting/conversion of RSUs), not an open-market purchase or voluntary sale; the only disposition was the issuer withholding shares for taxes.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (filed timely).
• Gross shares issued on settlement: 63,475 RSUs → 63,475 shares.
• Shares withheld for tax payment: 18,611 shares @ $3.47 = $64,580 (disposed under withholding code F).
• Net shares received: 44,864.
• Shares owned after transaction: not specified in the provided excerpt of the Form 4.
• Footnotes: F1 clarifies each RSU converts to one common share; F2 confirms share withholding satisfied tax obligations; F3 notes these RSUs vest in four equal annual installments starting Feb 3, 2025, subject to continuous service.

Context

• This is a routine RSU vesting/settlement event. The withholding of shares to cover taxes is common and does not necessarily indicate a trading view by the insider.
• The filing shows conversion/exercise treatment for the RSUs on the Form 4; no open-market purchases or voluntary sales (other than the tax-withholding disposition) were reported.